In addition, VGLL4 promotes pulmonary hypertension and pulmonary arterial remodeling through a signal transducer and the activation of transcription 3 (STAT3) signaling [158]; alternatively, the specific knockout of VGLL4 in ECs increases the YAP expression and heart valve malformation [159]. Here, STAT3 is linked to pulmonary arterial hypertension.